Crystallized oxalate decarboxylase and methods of use

Abstract

Oxalate decarboxylase crystals, including stabilized crystals, such as cross-linked crystals of oxalate decarboxylase, are disclosed. Methods to treat a disorder associated with elevated oxalate concentration using oxalate decarboxylase crystals are also disclosed. Additionally disclosed are methods of producing protein crystals.

1 . A pharmaceutical composition comprising an oxalate decarboxylase crystal. 
     
     
         2 . The composition of  claim 1 , wherein said crystal is more active than a soluble form of oxalate decarboxylase. 
     
     
         3 . The composition of  claim 2 , wherein the activity of said crystal is at least about 100% higher than the activity of the soluble form at pH 4. 
     
     
         4 . The composition of  claim 1 , wherein the oxalate decarboxylase crystal is crosslinked with a cross-linking agent and has at least about 100% of the activity of a soluble form of oxalate decarboxylase. 
     
     
         5 . The composition of  claim 4 , wherein the oxalate decarboxylase crystal is crosslinked with a cross-linking agent and has at least about 150% of the activity of the soluble form of oxalate decarboxylase. 
     
     
         6 . The composition of  claim 4 , wherein said cross-linking agent is glutaraldehyde. 
     
     
         7 . The composition of  claim 6 , wherein the oxalate decarboxylase crystal is crosslinked with about 0.02% to about 1.5% (w/v) glutaraldehyde. 
     
     
         8 . The composition of  claim 7 , wherein the crystal is cross-linked with about 0.5% 20 (w/v) glutaraldehyde. 
     
     
         9 . A method of reducing oxalate in a mammal, the method comprising administering a composition comprising oxalate decarboxylase crystals to the mammal in an amount sufficient to reduce the oxalate. 
     
     
         10 .- 17 . (canceled) 
     
     
         18 . A method of treating a disorder associated with elevated oxalate concentration in a mammal, the method comprising administering oxalate decarboxylase crystals to the mammal in an amount sufficient to reduce one or more symptoms associated with the disorder. 
     
     
         19 .- 33 . (canceled)